Acadia Pharmaceuticals Inc. has announced plans to initiate several new clinical studies as part of its expanding pipeline strategy. The company will begin a Phase 2 study for ACP-204 in Lewy Body Dementia Psychosis (LBDP) and a Phase 3 study in Japan for trofinetide in Rett syndrome, both scheduled for the third quarter of 2025. Additionally, early in the fourth quarter of 2025, Acadia will present topline results for the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi syndrome following the recent completion of enrollment. These developments are part of Acadia's broader initiative to advance care in neurological and rare diseases, with multiple study readouts anticipated by the end of 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250625948610) on June 25, 2025, and is solely responsible for the information contained therein.